Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Each of Two Dose Levels of Sarilumab in Adults With Early Polymyalgia Rheumatica

NCT07286214 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07286214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07286214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Each of Two Dose Levels of Sarilumab in Adults With Early Polymyalgia Rheumatica
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Recruiting
Start date
May 12, 2026
Completion date
July 16, 2029
Enrollment
300 (estimated)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

polymyalgia rheumatica